Modulation of blood-brain barrier function by a heteroduplex oligonucleotide in vivo

[1]  Y. Anraku,et al.  Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain , 2017, Nature Communications.

[2]  Jennifer L Marlowe,et al.  Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics. , 2017, Nucleic acid therapeutics.

[3]  N. Gogtay,et al.  Therapeutic nucleic acids: current clinical status , 2016, British journal of clinical pharmacology.

[4]  W. Banks,et al.  From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery , 2016, Nature Reviews Drug Discovery.

[5]  Christopher E. Hart,et al.  Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts , 2015, Nucleic acids research.

[6]  N. Saunders,et al.  Markers for blood-brain barrier integrity: how appropriate is Evans blue in the twenty-first century and what are the alternatives? , 2015, Front. Neurosci..

[7]  N. Grigoriadis,et al.  A basic overview of multiple sclerosis immunopathology , 2015, European journal of neurology.

[8]  Chenghua Gu,et al.  The Molecular Constituents of the Blood–Brain Barrier , 2015, Trends in Neurosciences.

[9]  K. Kataoka,et al.  DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing , 2015, Nature Communications.

[10]  W. Pardridge.  Blood–brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery , 2015, Expert opinion on therapeutic targets.

[11]  M. Behlke,et al.  Oligonucleotide Therapies: The Past and the Present , 2015, Human gene therapy.

[12]  C. Bennett,et al.  Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. , 2015, Advanced drug delivery reviews.

[13]  T. Yokota,et al.  Blood–brain barrier: A novel therapeutic target in multiple sclerosis , 2015 .

[14]  Luthfi Ramadani,et al.  Preliminary Investigation , 2015, 2015 Second International Conference on Computing Technology and Information Management (ICCTIM).

[15]  M. Sabbagh,et al.  Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer’s disease , 2015, Expert opinion on investigational drugs.

[16]  H. Mizusawa,et al.  Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol , 2015, Molecular therapy. Nucleic acids.

[17]  Amy Chan,et al.  Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. , 2014, Journal of the American Chemical Society.

[18]  T. Maniatis,et al.  An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex , 2014, The Journal of Neuroscience.

[19]  C. Wellington,et al.  HDL and cholesterol handling in the brain. , 2014, Cardiovascular research.

[20]  Zhonghan Li,et al.  Therapeutic targeting of microRNAs: current status and future challenges , 2014, Nature Reviews Drug Discovery.

[21]  Shuling Guo,et al.  Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice , 2014, Nucleic acids research.

[22]  Atsushi B. Tsuji,et al.  OAT3-Mediated Extrusion of the 99mTc-ECD Metabolite in the Mouse Brain , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  A. Burdick,et al.  Sequence motifs associated with hepatotoxicity of locked nucleic acid—modified antisense oligonucleotides , 2014, Nucleic acids research.

[24]  R. Ransohoff,et al.  Development, maintenance and disruption of the blood-brain barrier , 2013, Nature Medicine.

[25]  J. Ghiso,et al.  TRAIL death receptors DR4 and DR5 mediate cerebral microvascular endothelial cell apoptosis induced by oligomeric Alzheimer's Aβ , 2012, Cell Death and Disease.

[26]  A. Krainer,et al.  RNA therapeutics: beyond RNA interference and antisense oligonucleotides , 2012, Nature Reviews Drug Discovery.

[27]  H. Mizusawa,et al.  Efficient in vivo delivery of siRNA into brain capillary endothelial cells along with endogenous lipoprotein. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  F. Pfrieger,et al.  Cholesterol metabolism in neurons and astrocytes. , 2011, Progress in lipid research.

[29]  M. Helm,et al.  In vivo down-regulation of mouse brain capillary P-glycoprotein: A preliminary investigation , 2009, Neuroscience Letters.

[30]  H. Kusuhara,et al.  Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Res , 2009, Drug Metabolism and Disposition.

[31]  P. Humphries,et al.  RNAi‐mediated reversible opening of the blood‐brain barrier , 2008, The journal of gene medicine.

[32]  S. Maiti,et al.  Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA). , 2007, Chemical reviews.

[33]  A. Rigotti.  Absorption, transport, and tissue delivery of vitamin E. , 2007, Molecular aspects of medicine.

[34]  B. Monia,et al.  Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals , 2006, Nucleic acids research.

[35]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[36]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[37]  T. Kanda,et al.  In vivo delivery of small interfering RNA targeting brain capillary endothelial cells. , 2006, Biochemical and biophysical research communications.

[38]  S. Agrawal,et al.  Antisense and siRNA as agonists of Toll-like receptors , 2004, Nature Biotechnology.

[39]  Z. Balázs,et al.  Uptake and transport of high‐density lipoprotein (HDL) and HDL‐associated α‐tocopherol by an in vitro blood–brain barrier model , 2004, Journal of neurochemistry.

[40]  H. Kusuhara,et al.  Contribution of Organic Anion Transporter 3 (Slc22a8) to the Elimination of p-Aminohippuric Acid and Benzylpenicillin across the Blood-Brain Barrier , 2003, Journal of Pharmacology and Experimental Therapeutics.

[41]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[42]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[43]  R. Zechner,et al.  Effects of Lipoprotein Lipase on Uptake and Transcytosis of Low Density Lipoprotein (LDL) and LDL-associated α-Tocopherol in a Porcine in Vitro Blood-Brain Barrier Model* , 2002, The Journal of Biological Chemistry.

[44]  D. Beier,et al.  Impaired Organic Anion Transport in Kidney and Choroid Plexus of Organic Anion Transporter 3 (Oat3 (Slc22a8)) Knockout Mice* , 2002, The Journal of Biological Chemistry.

[45]  Xiaoxiang Zhu,et al.  A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase , 2001, Current medical research and opinion.

[46]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[47]  S. Marcus,et al.  Current Clinical Status , 2017 .

[48]  Koen Van Laer,et al.  Current status and future challenges , 2015 .

[49]  A. Schmidt,et al.  RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. , 1996, Nature.

[50]  F. Sánchez‐Madrid,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. , 1992, Nature.

[51]  E. Kreps,et al.  [From the past and the present]. , 1973, Zhurnal evoliutsionnoi biokhimii i fiziologii.